Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease

被引:51
作者
Arca, Marcello [1 ]
Montali, Anna
Valiante, Sofia
Campagna, Filomena
Pigna, Giovanni
Paoletti, Vincenzo
Antonini, Roberto
Barilla, Francesco
Tanzilli, Gaetano
Vestri, Annarita
Gaudio, Carlo
机构
[1] Univ Roma La Sapienza, Dept Clin & Med Therapy, Unit Med Therapy, I Med Sch, Rome, Italy
[2] Univ Roma La Sapienza, Dept Heart & Great Vessels Attilio Reale, I Med Sch, Rome, Italy
[3] Univ Roma La Sapienza, Dept Expt Med & Pathol, I Med Sch, Rome, Italy
关键词
D O I
10.1016/j.amjcard.2007.06.049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The identification of factors contributing to residual cardiovascular risk is important to improve the management of patients with established coronary artery disease (CAD). This study was conducted to assess the predictive value of atherogenic dyslipidemia (defined as high triglycerides and low high-density lipoprotein [HDL] cholesterol) for long-term outcomes in patients with CAD. In 284 patients (238 men, 46 women; mean age at baseline 59.2 +/- 8.9 years) with coronary stenosis (> 50% in >= 1 vessel), the presence of atherogenic dyslipidemia was prospectively associated with the incidence of major adverse cardiovascular events (MACEs) during a median follow-up of 7.8 years. MACEs were defined as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, the recurrence of angina, and revascularization procedures. MACEs were observed in 111 (39.1%) patients with CAD. MACEs occurred more frequently in patients with atherogenic dyslipidemia (50.9%) than in those with isolated low HDL cholesterol or high triglycerides (33.0%) or with normal HDL cholesterol and triglyceride concentrations (29.2%) (p < 0.01 for trend). Kaplan-Meier survival analysis showed a decrease in event-free survival in patients with compared with those without atherogenic dyslipidemia (log-rank p = 0.006). Patients with atherogenic dyslipidemia presented with increased plasma concentrations of remnants, denser low-density lipoprotein, more atherogenic HDL particles, and insulin-resistant status. After adjustment for potential confounding variables, the magnitude of increased risk associated with atherogenic dyslipidemia was 1.58 (95% confidence interval 1.12 to 2.21, p = 0.008). In conclusion, these data provide evidence that atherogenic dyslipidemia is an independent predictor of cardiovascular risk in patients with CAD, even stronger than isolated high triglycerides or low HDL cholesterol. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1511 / 1516
页数:6
相关论文
共 21 条
  • [1] HYPERCHOLESTEROLEMIA IN POSTMENOPAUSAL WOMEN - METABOLIC DEFECTS AND RESPONSE TO LOW-DOSE LOVASTATIN
    ARCA, M
    VEGA, GL
    GRUNDY, SM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (06): : 453 - 459
  • [2] Austen W G, 1975, Circulation, V51, P5
  • [3] Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI)
    Bittner, V
    Hardison, R
    Kelsey, SF
    Weiner, BH
    Jacobs, AK
    Sopko, G
    [J]. CIRCULATION, 2002, 106 (20) : 2537 - 2542
  • [4] Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the β3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia
    Campagna, F
    Montali, A
    Baroni, MG
    Maria, AT
    Ricci, G
    Antonini, R
    Verna, R
    Arca, M
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (10): : 1298 - 1305
  • [5] *EXP COMM DIAGN CL, 2000, DIABETES CARE S1, V23, pS4
  • [6] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
  • [7] Grundy Scott M, 2005, Clin Cornerstone, V7, P36, DOI 10.1016/S1098-3597(05)80066-3
  • [8] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, R
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Cleeman, JI
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    Keller, SA
    Jehle, AJ
    [J]. CIRCULATION, 2002, 106 (25) : 3143 - 3421
  • [9] ATHEROGENIC DYSLIPIDEMIA - LIPOPROTEIN ABNORMALITIES AND IMPLICATIONS FOR THERAPY
    GRUNDY, SM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (06) : B45 - B52
  • [10] 2003 European society of hypertension -: European Society of Cardiology guidelines for the management of arterial hypertension
    Mancia, G
    Rosei, EA
    Cifkova, R
    DeBacker, G
    Erdine, S
    Fagard, R
    Farsang, C
    Heagerty, AM
    Kawecka-Jaszcs, K
    Kiowski, W
    Kjeldsen, S
    Lüscher, T
    McInnes, G
    Mallion, JM
    Brien, EO
    Poulter, NR
    Priori, SG
    Rahn, KH
    Rodicio, JL
    Ruilope, LM
    Safar, M
    Staessen, JA
    van Zwieten, P
    Waeber, B
    Williams, B
    Zanchetti, A
    Zannad, F
    [J]. JOURNAL OF HYPERTENSION, 2003, 21 (06) : 1011 - 1053